Brokerage firm Morgan Stanley Maintains its rating on Portola Pharmaceuticals Inc(NASDAQ:PTLA). In a research note issued to the investors, the brokerage major Lowers the price-target to $28.00 per share. The shares have been rated Overweight. The rating by Morgan Stanley was issued on Aug 19, 2016.
In a different note, On Aug 10, 2016, Citigroup said it Maintains its rating on Portola Pharmaceuticals Inc. In the research note, the firm Raises the price-target to $38.00 per share. The shares have been rated ‘Buy’ by the firm. On May 31, 2016, Credit Suisse said it Downgrades its rating on Portola Pharmaceuticals Inc. In the research note, the firm Lowers the price-target to $33.00 per share. The shares have been rated ‘Neutral’ by the firm. On May 27, 2016, Citigroup said it Maintains its rating on Portola Pharmaceuticals Inc. In the research note, the firm Raises the price-target to $29.00 per share. The shares have been rated ‘Buy’ by the firm.
Portola Pharmaceuticals Inc (PTLA) made into the market gainers list on Mondays trading session with the shares advancing 1.09% or 0.22 points. Due to strong positive momentum, the stock ended at $20.38, which is also near the day’s high of $20.62. The stock began the session at $20.56 and the volume stood at 8,72,521 shares. The 52-week high of the shares is $57.955 and the 52 week low is $18.2. The company has a current market capitalization of $1,151 M and it has 5,65,01,022 shares in outstanding.
Portola Pharmaceuticals Inc(PTLA) last announced its earnings results on Aug 9, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $4.23M. Analysts had an estimated revenue of $4.38M. Earnings per share were $-1.02. Analysts had estimated an EPS of $-1.20.
Several Insider Transactions has been reported to the SEC. On May 3, 2016, William Lis (Chief Executive Officer) sold 5,675 shares at $23.86 per share price.Also, On Sep 21, 2015, Mardi Dier (Executive VP and CFO) sold 8,912 shares at $55.00 per share price.On Sep 18, 2015, Charles J Homcy (director) sold 40,067 shares at $56.25 per share price, according to the Form-4 filing with the securities and exchange commission.
Portola Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Companys two lead programs Betrixaban and Andexanet alfa address unmet medical needs in the area of thrombosis or blood clots. Its third product candidate is Cerdulatinib. The Company has a program of selective Syk inhibitors which is partnered with Biogen Idec Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa. Andexanet alfa is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor. Cerdulatinib is an orally available potent dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor.